期刊文献+

Network systems biology for targeted cancer therapies 被引量:1

Network systems biology for targeted cancer therapies
下载PDF
导出
摘要 The era of targeted cancer therapies has arrived.However,due to the complexity of biological systems,the current progress is far from enough.From biological network modeling to structural/dynamic network analysis,network systems biology provides unique insight into the potential mechanisms underlying the growth and progression of cancer cells.It has also introduced great changes into the research paradigm of cancer-associated drug discovery and drug resistance. The era of targeted cancer therapies has arrived. However, due to the complexity of biological systems, the current progress is far from enough. From biological network modeling to structural/dynamic network analysis, network systems biology provides unique insight into the potential mechanisms underlying the growth and progression of cancer cells. It has also introduced great changes into the research paradigm of cancer-associated drug discovery and drug resistance.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 2012年第3期134-141,共8页
基金 the National Natural Science Foundation of China (31100961,81173082,and 30873083)
关键词 系统生物学 网络分析 癌症 疗法 生物系统 模型结构 生物网络 药物发现 Targeted cancer therapy, network systems biology, network modeling, network analysis, drug discovery, drug resistance
  • 相关文献

参考文献85

  • 1Sawyers C. Targeted cancer therapy. Nature,2004,432:294 -297. 被引量:1
  • 2Gerber DE. Targeted therapies: a new generation of cancertreatments. Am Fam Physician,2008,77:311-319. 被引量:1
  • 3Gottesman MM,Fojo T,Bates SE. Multidrug resistance incancer: role of ATP-dependent transporters. Nat Rev Cancer,2002,2:48-58. 被引量:1
  • 4Khan S,Elshaer A,Rahman AS,et al. Genomic evaluationduring permeability of indomethacin and its solid dispersion. JDrug Target,2011,19:615-623. 被引量:1
  • 5Okada H,Mak TW. Pathways of apoptotic and non-apoptoticdeath in tumour cells. Nat Rev Cancer,2004,4:592-603. 被引量:1
  • 6Brown JM,Attardi LD. The role of apoptosis in cancerdevelopment and treatment response. Nat Rev Cancer,2005,5:231-237. 被引量:1
  • 7Pao W,Miller VA,Politi KA,et al. Acquired resistance of lungadenocarcinomas to gefitinib or erlotinib is associated with asecond mutation in the EGFR kinase domain. PLoS Med,2005,2:e73. 被引量:1
  • 8Shtil AA,Azare J. Redundancy of biological regulation as thebasis of emergence of multidrug resistance. Int Rev Cytol,2005,246:1-29. 被引量:1
  • 9Kellner U,Sehested M,Jensen PB,et al. Culprit and victim—DNA topoisomerase II. Lancet Oncol,2002,3:235-243. 被引量:1
  • 10Lage H. An overview of cancer multidrug resistance: a stillunsolved problem. Cell Mol Life Sci,2008,65:3145-3167. 被引量:1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部